Article Text

Download PDFPDF

Highlights from this issue
  1. Keith Barton,
  2. James Chodosh,
  3. Jost Jonas, Editors in Chief

Statistics from

Arevalo et al (see page 1605)

Intravitreal bevacizumab stabilizes BCVA in about 44% of the cases over the long-term and in the remainder, there may be a significant improvement or loss of BCVA. Systemic adverse events develop in 5.1% of patients.

Querques et al (see page 1611)

Outcomes of eyes with both neovascular age related macular degeneration and diabetic retinopathy showed stable or improved diabetic retinopathy severity with anti-vascular endothelial growth factor therapy.

McKibbin et al (see page 1617)

The likelihood of retreatment with ranibizumab for neovascular age-related macular degeneration reduces as the time without treatment increases. Nearly a third of eyes require retreatment within the next 12-months despite remaining injection-free for 12-months.

Sivaprasad et al (see page 1623)

Regression analysis of AURA revealed that a number of factors were predictive of treatment outcomes in a real-life setting, including age, baseline visual acuity score, number of injections, and regular monitoring.

Chhablani et al (see page 1629)

Off label use of ziv-aflibercept for wet age-related macular degeneration improves visual acuity, without any toxicity at …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles